ResMed CEO Sells 4,991 Shares After Option Exercise

ResMed Inc Chairman and CEO Michael J. Farrell exercised stock options and sold shares in a pre-planned transaction.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

ResMed Inc Chairman and CEO Michael J. Farrell exercised stock options and sold shares in a pre-planned transaction. He exercised options for 4,991 shares of ResMed common stock at an exercise price of $146.3400 per share, then sold 4,991 shares in open-market trades at a weighted average price of $218.5475 per share.

The sales were executed in multiple trades at prices ranging from $216.772 to $219.700 under a Rule 10b5-1 plan adopted on October 31, 2024. Following the transactions, Farrell directly holds 466,223 shares of ResMed common stock and indirectly holds 2,090 shares through the Lisette and Michael Farrell Family Trust, and 19,966 stock options remain outstanding.

Insider Trade Summary 10b5-1

Exercise and Sale: 4,991 shares ($360K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Farrell Michael J.

Role Chairman and CEO

Sold 4,991 shs ($1.09M)

Approx. gross sale proceeds $1.09M

Approx. exercise cost $730K

Approx. pre-tax spread $360K

Type	Security	Shares	Price	Value
Exercise	ResMed Common Stock Options	4,991	$0.00	$0.00
Exercise	ResMed Common Stock	4,991	$146.34	$730K
Sale	ResMed Common Stock	4,991	$218.5475	$1.09M
holding	ResMed Common Stock	--	--	--

Holdings After Transaction: ResMed Common Stock Options — 19,966 contracts (Direct); ResMed Common Stock — 466,223 shares (Direct); ResMed Common Stock — 2,090 shares (Indirect, Lisette and Michael Farrell Family Trust)

Footnotes (3)

F1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
F2. This transaction was executed in multiple trades at prices ranging from $216.772 - $219.700. The price reported above reflects the weighted average sale price.
F3. Represents date options first become exercisable. Options vest 1/3 per year.

Key Figures

Shares sold: 4,991 shares Weighted average sale price: $218.5475 per share Sale price range: $216.772–$219.700 per share +5 more

8 metrics

Shares sold 4,991 shares Open-market sale of ResMed Common Stock

Weighted average sale price $218.5475 per share Open-market sale on July 7, 2026

Sale price range $216.772–$219.700 per share Multiple trades on transaction date

Option exercise price $146.3400 per share ResMed Common Stock Options exercised

Direct holdings after transaction 466,223 shares ResMed Common Stock directly owned by CEO

Indirect holdings after transaction 2,090 shares Held via Lisette and Michael Farrell Family Trust

Options remaining 19,966 options ResMed Common Stock Options outstanding

Rule 10b5-1 plan adoption date October 31, 2024 Plan governing the reported sale

Key Terms

Rule 10b5-1 plan, weighted average sale price, ResMed Common Stock Options, open-market sale

4 terms

Rule 10b5-1 plan financial

"The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

ResMed Common Stock Options financial

"Security title is listed as ResMed Common Stock Options with underlying ResMed Common Stock."

open-market sale financial

"Transaction action is described as an open-market sale."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ResMed (RMD) CEO Michael Farrell report?

Michael J. Farrell reported exercising options for 4,991 ResMed shares at $146.3400 and selling 4,991 shares at a weighted average price of $218.5475. The sale was an open-market transaction executed under a pre-arranged Rule 10b5-1 trading plan.

How many ResMed (RMD) shares does Michael Farrell hold after this Form 4?

After the reported transactions, Michael J. Farrell directly holds 466,223 shares of ResMed common stock and indirectly holds 2,090 shares through the Lisette and Michael Farrell Family Trust. He also has 19,966 stock options remaining outstanding, according to the filing data.

At what prices did the ResMed (RMD) CEO sell his shares?

The reported 4,991 ResMed shares were sold at a weighted average price of $218.5475 per share. The filing notes multiple trades executed in a price range from $216.772 to $219.700, reflecting typical execution across several market transactions.

What was the exercise price of Michael Farrell’s ResMed (RMD) stock options?

The exercised stock options covered 4,991 ResMed shares at an exercise price of $146.3400 per share. These options relate to ResMed Common Stock Options that first became exercisable on November 11, 2020, with vesting at one-third per year, as described in the footnotes.

Was the ResMed (RMD) CEO’s stock sale part of a Rule 10b5-1 plan?

Yes. The filing states that Michael J. Farrell’s transaction was conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024. Such pre-arranged plans allow insiders to schedule trades in advance, reducing discretion over the timing of sales.

How many ResMed (RMD) stock options remain after Michael Farrell’s exercise?

Following the option exercise for 4,991 shares, the filing shows 19,966 ResMed Common Stock Options remaining outstanding for Michael J. Farrell. These options are associated with an original grant that vests in thirds annually and has an expiration date of November 21, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/09/2026 - 07:40 AM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrell Michael J.

(Last)

(First)

(Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO

CALIFORNIA

92123

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
ResMed Common Stock	07/07/2026		M⁽¹⁾		4,991	A	$146.34	471,214	D
ResMed Common Stock	07/07/2026		S⁽¹⁾		4,991	D	$218.5475⁽²⁾	466,223	D
ResMed Common Stock								2,090	I	Lisette and Michael Farrell Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
ResMed Common Stock Options	$146.34	07/07/2026		M⁽¹⁾			4,991	11/11/2020⁽³⁾	11/21/2026	ResMed Common Stock	4,991	$0	19,966	D

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

2. This transaction was executed in multiple trades at prices ranging from $216.772 - $219.700. The price reported above reflects the weighted average sale price.

3. Represents date options first become exercisable. Options vest 1/3 per year.

	/s/ Michael J. Farrell, Chairman and CEO	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR